Literature DB >> 29415188

Phase I-II trial designs: how early should efficacy guide the dose recommendation process?

X Paoletti1, S Postel-Vinay2.   

Abstract

Mesh:

Year:  2018        PMID: 29415188     DOI: 10.1093/annonc/mdy044

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.

Authors:  Mei-Yin C Polley; Ying Kuen Cheung
Journal:  JCO Precis Oncol       Date:  2019-10-24

2.  Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Authors:  Rebecca S S Tidwell; Peter F Thall; Ying Yuan
Journal:  JCO Precis Oncol       Date:  2021-11-10

3.  CFO: Calibration-free odds design for phase I/II clinical trials.

Authors:  Huaqing Jin; Guosheng Yin
Journal:  Stat Methods Med Res       Date:  2022-03-03       Impact factor: 2.494

4.  Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.

Authors:  Shing M Lee; Nolan A Wages; Karyn A Goodman; A Craig Lockhart
Journal:  JCO Precis Oncol       Date:  2021-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.